Key facts
- Exeliom Biosciences’s last known valuation is $7.4M (Dec 2018).
- It has raised $33.3M; the latest was Later Stage VC ($3.3M) in Oct 2025.
- Notable investors include Bpifrance, European Innovation Council, UI Investissement, Elaia Partners, CE-Ventures — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Exeliom Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Exeliom Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Exeliom Biosciences
Developer of immunotherapies designed to help harness the therapeutic potential of gut microbiota. The company develops single bacterial strain drug candidates to deliver microbiome-based immunotherapy for treating inflammatory bowel diseases and cancer, starting with Crohn's Disease as a first indication, enabling patients to lead longer and healthier lives by accessing their medicines derived from microbiota.
- Sector
- Healthcare
- HQ
- Dijon, France
- Founded
- 2016
- Employees
- 8
- Website
- exeliombio.com/
- Ownership
- Privately Held (backing)
Exeliom Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Exeliom Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Exeliom Biosciences in its N-PORT filings yet. We sweep new filings monthly.